Shareholders' Deficit (Tables)
|
12 Months Ended |
Jan. 03, 2026 |
|---|
| Share-Based Payment Arrangement [Abstract] |
|
| Schedule of Stock-Based Compensation Expense |
Total stock-based compensation expense was as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | Total stock-based compensation expense(1) | | | | | |
(1)Changes in annual stock-based compensation expense includes the cumulative impact of the change in the expected achievements of certain performance targets.
|
| Schedule of Stock Option Activity |
A summary of the Company’s stock option activity was as follows (in thousands, except per share amounts and years): | | | | | | | | | | | Weighted- Average Exercise Price per Share | | Weighted- Average Remaining Contractual Term (years) | | Aggregate Intrinsic Value(1) | Outstanding at December 28, 2024 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Outstanding at January 3, 2026 | | | | | | | | Exercisable at January 3, 2026 | | | | | | | | Vested and expected to vest at January 3, 2026 | | | | | | | |
(1)Aggregate intrinsic value includes only those options where the current share price is equal to or greater than the share price on the date of grant.
|
| Schedule of Other Information Pertaining to Options |
Other information pertaining to options was as follows (in thousands, except per share amounts): | | | | | | | | | | | | Weighted-average grant date fair value of stock options granted | | | | | | Total intrinsic value (at exercise) of stock options exercised | | | | | |
|
| Schedule of Assumptions Used to Calculate Fair Value of Options Granted Using Black-Scholes-Merton Option-Pricing Model |
The assumptions used to calculate the fair value of options granted using the Black-Scholes-Merton option-pricing model were as follows. There were no grants of new stock option awards for the fiscal year ended January 3, 2026 or December 28, 2024.
|
| Schedule of Stock Award Activity |
Stock award activity was as follows (in thousands, except per share amounts): | | | | | | | | | | | Weighted- Average Grant Date Fair Value | | Performance- Based Stock Awards | | Weighted- Average Grant Date Fair Value | Outstanding at December 28, 2024 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Outstanding at January 3, 2026 | | | | | | | |
|
| Schedule of Repurchase of Common Stock |
Repurchases of the Company’s common stock were as follows (in thousands): | | | | | | | | | | | | Amount repurchased under Board-approved share repurchase program | | | | | | Amount repurchased in connection with the vesting of employee restricted stock grants | | | | | | Total amount repurchased (based on trade dates) | | | | | |
|
| Schedule of Components of Basic and Diluted Net Loss per Common Share |
The components of basic and diluted net loss per share were as follows (in thousands, except per share amounts): | | | | | | | | | | | | | | | | | | Reconciliation of weighted-average shares outstanding: | | | | | | Basic weighted-average shares outstanding | | | | | | Dilutive effect of stock-based awards | | | | | | Diluted weighted-average shares outstanding | | | | | | Net loss per share – basic and diluted | | | | | |
|